On Monday, Macrogenics Inc (NASDAQ: MGNX) opened higher 0.60% from the last session, before settling in for the closing price of $18.24. Price fluctuations for MGNX have ranged from $4.29 to $21.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 15.77% over the last five years. Company’s average yearly earnings per share was noted -1599.45% at the time writing. With a float of $58.56 million, this company’s outstanding shares have now reached $62.07 million.
The firm has a total of 339 workers. Let’s measure their productivity.
Macrogenics Inc (MGNX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Macrogenics Inc is 6.21%, while institutional ownership is 95.44%. The most recent insider transaction that took place on Apr 04 ’24, was worth 799,148. In this transaction Senior VP and General Counsel of this company sold 51,395 shares at a rate of $15.55, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 06 ’24, when Company’s Senior VP and General Counsel sold 19,625 for $21.50, making the entire transaction worth $421,938. This insider now owns 8,895 shares in total.
Macrogenics Inc (MGNX) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 12/30/2023, the company posted -$0.75 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.15) by -$0.6. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.63 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1599.45% per share during the next fiscal year.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Check out the current performance indicators for Macrogenics Inc (MGNX). In the past quarter, the stock posted a quick ratio of 4.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.15, a number that is poised to hit -0.62 in the next quarter and is forecasted to reach -1.87 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Analysing the last 5-days average volume posted by the [Macrogenics Inc, MGNX], we can find that recorded value of 2.84 million was better than the volume posted last year of 1.52 million. As of the previous 9 days, the stock’s Stochastic %D was 85.97%. Additionally, its Average True Range was 1.34.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 77.57%, which indicates a significant decrease from 89.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 120.22% in the past 14 days, which was higher than the 77.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.63, while its 200-day Moving Average is $9.02. Now, the first resistance to watch is $18.70. This is followed by the second major resistance level at $19.06. The third major resistance level sits at $19.40. If the price goes on to break the first support level at $18.00, it is likely to go to the next support level at $17.66. Now, if the price goes above the second support level, the third support stands at $17.30.
Macrogenics Inc (NASDAQ: MGNX) Key Stats
There are currently 62,432K shares outstanding in the company with a market cap of 1.15 billion. Presently, the company’s annual sales total 58,750 K according to its annual income of -9,060 K. Last quarter, the company’s sales amounted to 10,720 K and its income totaled -46,070 K.
